Top

Published in:

01-07-2023 | Liraglutide | News item

Semaglutide, liraglutide: risk of suicidal ideation and self-injury

Published in: Reactions Weekly | Issue 1/2023

Excerpt

The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) is reviewing data on the risk of suicidal ideation and self-injury with glucagon-like peptide-1 (GLP-1) receptor agonists including Ozempic (semaglutide), Saxenda (liraglutide) and Wegovy (semaglutide). The three drugs are used for the treatment of type 2 diabetes mellitus, and Saxenda and Wegovy are also authorised for weight management. …

EMA statement on ongoing review of GLP-1 receptor agonists Internet Document : 11 Jul 2023. Available from: URL: https://www.ema.europa.eu/en/news/ema-statement-ongoing-review-glp-1-receptor-agonists

Title: Semaglutide, liraglutide: risk of suicidal ideation and self-injury
Publication date: 01-07-2023
Publisher: Springer International Publishing
Keywords: Liraglutide
Dulaglutid
Exenatide
Semaglutide
Incretin Mimetics
Incretin Mimetics
Published in: Reactions Weekly / Issue 1/2023
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-023-43459-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Semaglutide, liraglutide: risk of suicidal ideation and self-injury

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2023

Antineoplastics/ribavirin

Antihyperglycaemics

Multiple drugs

Dalteparin-sodium

AZD-1222/tozinameran

Prednisone/tinzaparin-sodium